Inventiva Will Present Findings from Maroteaux-Lamy Syndrome Trial at Upcoming Conference
source: pixabay.com

Inventiva Will Present Findings from Maroteaux-Lamy Syndrome Trial at Upcoming Conference

According to a story from globenewswire.com, the biopharmaceutical company Inventiva is scheduled to present the findings from a recent phase IIa clinical trial at the upcoming 16th Annual WorldSymposium™ which is…

Continue Reading Inventiva Will Present Findings from Maroteaux-Lamy Syndrome Trial at Upcoming Conference
Study: Odiparcil Shows Positive Results in Treatment of Mucopolysaccharidosis Type VI (MPS VI)
jarmoluk / Pixabay

Study: Odiparcil Shows Positive Results in Treatment of Mucopolysaccharidosis Type VI (MPS VI)

Inventiva has recently completed Phase IIa of their clinical trial of odiparcil, a drug made for the treatment of mucopolysaccharidosis type VI (MPS VI). Iventiva is very excited about the…

Continue Reading Study: Odiparcil Shows Positive Results in Treatment of Mucopolysaccharidosis Type VI (MPS VI)
First Patients Recruited in Maroteaux-Lamy Syndrome Biomarker Study
felixioncool / Pixabay

First Patients Recruited in Maroteaux-Lamy Syndrome Biomarker Study

According to a story from Benzinga, the biopharmaceutical company Inventiva has recently announced that it has recruited the first patients in a study of biomarkers in Maroteaux-Lamy syndrome. The study…

Continue Reading First Patients Recruited in Maroteaux-Lamy Syndrome Biomarker Study

UPDATE: Trump Admin Reconsiders Decision to Deport Migrants Receiving Life-Saving Treatment 

Last week, we spotlighted a New York Times story about how under the Trump Administration’s new immigration policy, six migrants undergoing lifesaving treatments would be abruptly deported; including a young woman…

Continue Reading UPDATE: Trump Admin Reconsiders Decision to Deport Migrants Receiving Life-Saving Treatment 

Patient Recruitment Completed for Phase 2 Study of Mucopolysaccharidosis VI Drug Candidate

According to a press release from the French biotechnology company Inventiva, the company has completed recruitment for a phase 2 clinical trial evaluating its experimental mucopolysaccharidosis VI drug, odiparcil. About…

Continue Reading Patient Recruitment Completed for Phase 2 Study of Mucopolysaccharidosis VI Drug Candidate
This Just In: India Never Implemented their Rare Disease Policy as Promised
Source: Pixabay.com

This Just In: India Never Implemented their Rare Disease Policy as Promised

We all got really excited last year when India implemented a new plan to benefit rare disease patients. It was called the National Rare Disease Policy. Basically, it put 12.86…

Continue Reading This Just In: India Never Implemented their Rare Disease Policy as Promised
Close Menu